153 results match your criteria: "Myelodysplastic Syndromes Unclassifiable"
Background: The aim of the study was to improve the clinical cognition of nonaccelerating myelodysplastic/myeloproliferative neoplasms-unclassifiable (MDS/MPN-U) with 5q- karyotype and to avoid misdiagnosis or delayed diagnosis.
Methods: The clinical manifestations and laboratory results of a patient with nonaccelerating MDS/MPN-U with 5q- karyotype were analyzed, and related literature was reviewed.
Results: The patient was admitted to hospital mainly due to chest tightness and shortness of breath, aggravated for 4 days.
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
Int J Mol Sci
September 2024
Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Article Synopsis
- Scientists are trying to figure out how to diagnose different types of blood disorders called MDS and MPN, which can be tricky because they have some similar features.
- They looked at the DNA of patients with different types of these disorders to see how they are different and found specific gene mutations that can help identify each type.
- The research shows that age and certain mutations can affect how well patients do, and this information can help doctors make better decisions about treatment.
Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.
Intern Med
March 2024
Department of Hematology, Kin-ikyo Chuo Hospital, Japan.
Article Synopsis
- Azacitidine (AZA) is a common treatment for older patients with serious blood disorders called myelodysplastic syndromes (MDS), but it's hard to predict how well it will work for each person.
- In a study with 29 patients who started treatment, researchers looked at a type of hemoglobin in the blood called fetal hemoglobin (HbF) to see if it could help predict outcomes.
- They found that patients with higher HbF levels before treatment did better, showing more improvement in their health and living longer than those with normal HbF levels.
A case of Behçet's-like disease associated with trisomy 8-positive myelodysplastic syndrome carrying MEFV E148Q variant presented with periodic fever.
Mod Rheumatol Case Rep
June 2023
Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan.
Article Synopsis
- An 82-year-old man was found to have Behçet's-like disease and myelodysplastic syndrome (MDS), which is a blood disorder.
- He experienced joint pain and a fever that happened every two weeks for three months, and tests showed problems in his colon and bone marrow.
- The doctors tried different treatments, but only one medicine, canakinumab, helped a little with his fever, highlighting the need to check for MDS in older patients with similar symptoms.
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Bone Marrow Transplant
February 2023
CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000 Lille, Lille, France.
The International Consensus Classification of myelodysplastic syndromes and related entities.
Virchows Arch
January 2023
Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- The International Consensus Classification (ICC) has updated how we classify myelodysplastic syndromes (MDS), putting them into a bigger group with other related conditions.
- It defines MDS mainly by certain changes in blood cells, which help doctors tell it apart from other blood disorders.
- The ICC has introduced new categories that recognize genetic mutations and has simplified the classification from 8 to 7 different types of MDS.
[Haploidentical hematopoietic stem cell transplantation for graft failure in myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable complicated with Stenotrophomonas maltophilia bacteremia].
Rinsho Ketsueki
September 2022
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Article Synopsis
- A 60-year-old woman with a blood disorder got a bone marrow transplant from a matched male donor.
- After some time, she had issues with her blood cells and got sick from a type of bacteria called Stenotrophomonas maltophilia.
- She eventually received another transplant from her son, which helped her recover and allowed her to go home after her illness was treated.
Article Synopsis
- Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are a group of blood diseases where the bone marrow doesn’t make blood cells properly, leading to problems like low blood cell counts and overproduction of certain cells.
- Recent research has helped scientists understand the genetic changes that happen in these diseases, such as specific chromosome issues and mutations that affect how blood cells grow.
- Different types of MDS/MPN have their own unique genetic features, and knowing these can help doctors predict how serious the disease might be and improve treatment for patients.
Automated analysers underestimate atypical basophil count in myeloid neoplasms.
Int J Lab Hematol
October 2022
Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Article Synopsis
- A study was conducted to investigate how well automated analysers count basophils in patients with myeloid disorders like myeloproliferative neoplasms (MPNs), compared to manual methods and flow cytometry.
- The results showed that the automated analysers significantly underestimated basophil counts in these patients compared to manual and flow cytometric measurements.
- The findings suggest that relying solely on automated analysers could lead to inaccurate basophil quantification in individuals with myeloid neoplasms, and manual differential and flow cytometry techniques are preferred for accurate results.
Article Synopsis
- The study looks at a type of blood cancer called MDS/MPN-RS-T, which was officially recognized in 2016.
- Researchers checked the medical records of patients diagnosed with similar conditions between 2008 and 2018.
- Out of 8 patients studied, none showed specific symptoms, but they found mutations in some cases, and they emphasized the importance of careful testing for accurate diagnosis.
MDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene.
Cytogenet Genome Res
March 2022
Laboratory Medicine Program, University Health Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Article Synopsis
- MDS/MPN-U is a type of blood disorder that doctors don’t fully understand yet.
- Recent research showed that different people with this disorder have different genetic changes.
- This report is special because it's the first time someone found a specific genetic change in a person with MDS/MPN-U that created a new gene combination.
Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Front Oncol
November 2021
Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Hospital Duesseldorf, Duesseldorf, Germany.
Article Synopsis
- Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) are a group of illnesses affecting blood cells that have some similar traits, but are also quite different.
- The main disease in this group is chronic myelomonocytic leukemia (CMML), which is more common than the others, like atypical chronic myeloid leukemia and juvenile myelomonocytic leukemia.
- Diagnosing these diseases can be tricky because doctors have to look at cell shapes and features, and the review talks about important information on how to recognize and understand these blood disorders.
Article Synopsis
- Myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) are serious blood diseases that affect how blood is made in the bone marrow and can have mixed symptoms.
- These diseases usually happen in older people, especially those who have had certain blood disorders or treatments before, but they don’t often appear after someone has been treated for acute myeloid leukemia (AML).
- In a unique case, a patient who was treated for AML ended up developing MDS/MPN-unclassifiable after 4 years, even though there were no signs of the original leukemia coming back.
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
J Allergy Clin Immunol
January 2022
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address:
Article Synopsis
- A new disease called VEXAS affects older men who have specific mutations in a gene called UBA1, leading to serious inflammation and health problems.
- The study looked back at records of patients who had been diagnosed with unclear autoinflammatory issues to find cases of VEXAS.
- Twelve men were found with this disease, which often doesn’t respond to treatment and can lead to serious complications, emphasizing the importance of early diagnosis for better care.
Are We Undercounting MDS? An Analysis of Incidence Patterns of Myelodysplastic Syndromes in SEER 21 Regions: 2001-2016.
J Registry Manag
January 2021
Cancer Registry of Greater California, Public Health Institute, Sacramento, California.
Article Synopsis
- Myelodysplastic syndromes (MDSs) are not very well understood and have been tracked since 2001 to learn more about them.
- A study looked at how often MDS cases happened from 2001 to 2016, considering updates in how cases were coded in 2010.
- The results showed that MDS cases increased until 2010 and then decreased, especially in a common subtype called MDS-U, likely due to the changes in reporting methods.
Article Synopsis
- Myelodysplastic syndrome (MDS) is a group of serious illnesses that affect how your bone marrow works, which makes blood cells.
- Between 2001 and 2016, the number of people diagnosed with MDS changed, and some types are becoming less common.
- The decline in one type of MDS (called MDS-U) might be due to better health care and treatments over the years.
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Hematology Am Soc Hematol Educ Program
December 2020
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Article Synopsis
- Myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) overlap syndromes are types of blood cancer that can happen in both kids and adults, and there are 5 main types of them.
- Most patients have gene mutations, and while no single gene points to a specific type, certain gene patterns can help doctors figure out what illness a person has.
- Treatments can depend on finding these mutations since some can help doctors decide which therapies might work best.
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Hematology Am Soc Hematol Educ Program
December 2020
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Article Synopsis
- * CMML is characterized by persistent monocytosis and specific genetic mutations, with patients often presenting in their 70s and facing a median survival of less than 36 months; common risk factors include older age, high white blood cell counts, and low platelet counts.
- * Although allogeneic stem cell transplantation is the only cure, many patients are ineligible due to age
Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
Hematol Oncol Stem Cell Ther
June 2022
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Article Synopsis
- Myelodysplastic syndrome (MDS) is a challenging blood disorder linked to ineffective blood cell production and difficulty diagnosing due to vague symptoms and unclear criteria.
- Researchers analyzed medical records of 183 patients with severe cytopenias at a Saudi Arabian hematology lab from 2009 to 2016 to improve diagnosis of MDS.
- The study found that MDS was diagnosed in over half of the adult patients, revealing various subtypes and a high rate of specific chromosome abnormalities, highlighting the complexity and diagnostic challenges of the condition.
Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Front Oncol
October 2020
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China.
Dysplasia and proliferation are histological properties that can be used to diagnose and categorize myeloid tumors in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). However, these conditions are not exclusive, and overlap between them leads to another classification, MDS/MPN. As well as phenotype continuity, these three conditions may have genetic relationships that have not yet been identified.
View Article and Find Full Text PDFOligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Blood Adv
October 2020
Laboratori de Citologia Hematològica, Servei de Patologia, Grup de Recerca Translacional en Neoplàsies Hematològiques (GRETNHE), and.
Article Synopsis
- Oligomonocytic chronic myelomonocytic leukemia (OM-CMML) is a type of blood cancer that has features similar to another type called chronic myelomonocytic leukemia (CMML), but is classified differently.
- Researchers studied 40 patients with OM-CMML and compared them to 56 patients with CMML and found that both groups had a lot in common in terms of symptoms and genetic profiles, but OM-CMML had fewer specific gene mutations.
- Tests showed that certain characteristics in the blood could help doctors accurately determine if someone has CMML, which supports the idea that OM-CMML should be viewed as its own special type of CMML.
Molecular genetics of MDS/MPN overlap syndromes.
Best Pract Res Clin Haematol
September 2020
Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address:
Article Synopsis
- The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are different types of blood cancers that have features similar to two other groups of blood disorders.
- These cancers include types like chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia, recognized by health experts.
- New genetic studies are helping doctors understand how these cancers develop and how they can use this knowledge to make better treatment choices.
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Blood
October 2020
Munich Leukemia Laboratory (MLL), Munich, Germany.
Article Synopsis
- * A study characterized the mutations in 367 adults with different MDS/MPN subtypes, identifying 30 recurrently mutated genes and noting differences in mutation patterns across the subtypes.
- * Specific gene combinations were linked to distinct subtypes and influenced patient outcomes, providing insights that could improve clinical decision-making for treating these neoplasms.
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Best Pract Res Clin Haematol
June 2020
Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, USA; Yale Cancer Center, New Haven, USA.
Article Synopsis
- MDS (Myelodysplastic Syndromes) and MPN (Myeloproliferative Neoplasms) can sometimes happen together, and that's why there's a category called MDS/MPN.
- Some patients don't fit exactly into the known subcategories, so they are called MDS/MPN-unclassifiable (MDS/MPN-U), which has been improved over time as we learn more about it.
- Scientists found mutations like SF3B1 that help separate some cases, showing that MDS/MPN-U doesn't have to be a catch-all group forever, and we might find better ways to classify these patients in the future.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
September 2020
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- * The primary findings show a 3-year overall survival rate of 48.5%, with significant influences from patient age and disease progression on survival outcomes.
- * Results indicate that although allo-HSCT could be a potential cure for MDS/MPN-U, factors like being age 50 or older and having disease progression negatively impact overall survival.